Skip to main content
Premium Trial:

Request an Annual Quote

Sapphiros Launched to Invest in Growth-Stage Dx Firms; Acquires POC Test Developer Biocrucible

NEW YORK — Investment firm KKR said on Wednesday that it formed a company to invest in growth-stage diagnostic companies in partnership with industry veteran Namal Nawana.

The new company, called Sapphiros, has signed an agreement to acquire UK-based startup Biocrucible, which is developing point-of-care molecular diagnostics based on a proprietary isothermal nucleic acid amplification technology, KKR said. Sapphiros has also taken an unspecified equity stake in GrapheneDx, a developer of at-home consumer diagnostic devices based in Cambridge, Massachusetts.

According to KKR, Namal Nawana, who previously served as CEO of medical equipment manufacturer Smith+Nephew and diagnostics firm Alere, will oversee Sapphiros as its executive chairman.

"As the era of sophisticated at-home and near-patient testing rapidly expands, particularly following the global pandemic, new technologies are required to respond to consumers' unmet needs," Nawana said in a statement. "We established Sapphiros not only to identify and invest in these new technologies but also to help deliver them at scale."

In late 2019, KKR sold life science tools company LGC, which it acquired in 2015, to a consortium of private equity firms.

The Scan

Removal Inquiry

The Wall Street Journal reports that US lawmakers are seeking additional information about the request to remove SARS-CoV-2 sequence data from a database run by the National Institutes of Health.

Likely to End in Spring

Free lateral flow testing for SARS-CoV-2 may end in the UK by next spring, the head of Innova Medical Group says, according to the Financial Times.

Searching for More Codes

NPR reports that the US Department of Justice has accused an insurance and a data mining company of fraud.

Genome Biology Papers on GWAS Fine-Mapping Method, COVID-19 Susceptibility, Rheumatoid Arthritis

In Genome Biology this week: integrative fine-mapping approach, analysis of locus linked to COVID-19 susceptibility and severity, and more.